Condition: Neovascular Age-Related Macular Degeneration (nAMD) · Wet AMD · Sponsor: Adverum Biotechnologies, Inc.
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to intravitreal aflibercept (active comparator). The primary endpoint of this study is the mean change in best corrected visual acuity (BCVA) of Ixo-vec compared to an active comparator measured as an average at Weeks 52 and 56. Safety, tolerability, and efficacy will be evaluated throughout the study.
This description comes directly from the study's public registry record.
Adverum Study Contact · 650-656-9323 · ADVM02213ClinOp@adverum.com
Always discuss trial participation with your own doctor first.
| Adverum Clinical Site 245 | Mesa, Arizona, United States | Recruiting |
| Adverum Clinical Site 126 | Phoenix, Arizona, United States | Recruiting |
| Adverum Clinical Site 178 | Phoenix, Arizona, United States | Recruiting |
| Adverum Clinical Site 223 | Phoenix, Arizona, United States | Recruiting |
| Adverum Clinical Site 229 | Scottsdale, Arizona, United States | Recruiting |
| Adverum Clinical Site 242 | Sun City, Arizona, United States | Recruiting |
| Adverum Clinical Site 198 | Springdale, Arkansas, United States | Recruiting |
| Adverum Clinical Site 109 | Bakersfield, California, United States | Recruiting |
| Adverum Clinical Site 100 | Beverly Hills, California, United States | Recruiting |
| Adverum Clinical Site 201 | Campbell, California, United States | Recruiting |
| Adverum Clinical Site 172 | Encino, California, United States | Recruiting |
| Adverum Clinical Site 169 | Fullerton, California, United States | Recruiting |
+ 67 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07482176